Get the Stockscreener App
1.2907
2.26%
-0.0293
Nrx Pharmaceuticals Inc stock is traded at $1.2907, with a volume of 54,604.
It is down -2.26% in the last 24 hours and down -16.22% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
54,604
Relative Volume:
0.51
Market Cap:
$14.19M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-2.2644
EPS:
-0.57
Net Cash Flow:
$-21.66M
1W Performance:
+1.59%
1M Performance:
-16.22%
6M Performance:
-38.56%
1Y Performance:
-60.62%
1-Day Range:
$1.275
$1.35
1-Week Range:
$1.2278
$1.45
52-Week Range:
$1.10
$7.333
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals (NASDAQ:NRXP) Publishes Shareholder Update L - GuruFocus.com
NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule - GlobeNewswire
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq th - GuruFocus.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - StockTitan
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Unde - GuruFocus.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024 - GuruFocus.com
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report Second Quarte - GuruFocus.com
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2 - GuruFocus.com
NRx Pharmaceuticals, Inc. and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - Marketscreener.com
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE - GlobeNewswire
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - StockTitan
EF Hutton Acquisition Co. I Upgrades NRx Pharmaceuticals (NASDAQ:NRXP) to Strong-Buy - Defense World
Can Nrx combination unlock NMDA’s oomph in akathisia? - BioWorld Online
EF Hutton sets stock target on NRx Pharma, cites suicide prevention - Investing.com India
NRx started at buy by EF Hutton, cites suicide prevention focus - MSN
NRx started at buy by EF Hutton, cites suicide prevention focus (NASDAQ:NRXP) - Seeking Alpha
NRx Pharmaceuticals secures additional $5 million funding By Investing.com - Investing.com Nigeria
NRx Pharmaceuticals secures additional $5 million funding - Investing.com India
NRx Pharmaceuticals announces CEO resignation and stockholder votes - Investing.com
NRx Pharmaceuticals announces CEO resignation and stockholder votes By Investing.com - Investing.com Canada
NRx Pharmaceuticals Leadership Shift and Strategic Governance Decisions - Yahoo Finance
NRx Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - Marketscreener.com
NRXP stock touches 52-week low at $1.33 amid market challenges - Investing.com
NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding from Streeterville Capital, LLC - Marketscreener.com
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MSN
HOPE Therapeutics and NRx Pharmaceuticals to Acquire a Premier West Coast Interventional Psychiatric Clinic - citybiz
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic - cnhinews.com
NRXP stock touches 52-week low at $1.59 amid market challenges - Investing.com Australia
NRXP stock touches 52-week low at $1.59 amid market challenges By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Streamlines Operations to Enhance YCANTH Access - MyChesCo
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) - The Malaysian Reserve
NRx reports stable ketamine for suicidal depression treatment By Investing.com - Investing.com Australia
NRX-100 (Ketamine) Reaches Stability Milestone - Contract Pharma
NRx reports stable ketamine for suicidal depression treatment - Investing.com
NRx Pharmaceuticals Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) - citybiz
NRx Pharmaceuticals Featured on Psychiatrist.com - citybiz
Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 5.2% - Defense World
Energy Vault Holdings Inc (NRGV) expanding its growth trajectory ahead - SETE News
Market Insights: Recursion Pharmaceuticals Inc (RXRX)’s Notable Gain of 1.65, Closing at 6.76 - The Dwinnex
Rocket Pharmaceuticals’ (RCKT) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
The Significance of Moving Averages in Recursion Pharmaceuticals Inc Inc. (RXRX) Price Performance - The InvestChronicle
Meeder Advisory Services Inc. Increases Stake in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Market Update: Energy Vault Holdings Inc (NRGV) Sees Negative Movement, Closing at 0.79 - The Dwinnex
NRx Pharmaceuticals’ Innovative Treatments for Depression Gain Spotlight - MSN
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by State of New Jersey Common Pension Fund D - Defense World
Reneo Pharmaceuticals Inc (RPHM) rating downgrades by Leerink Partners - Knox Daily
Reneo Pharmaceuticals executive buys shares worth over $484k By Investing.com - Investing.com Canada
Recursion Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):